With positive top-line results released from the Phase III ARAMIS study involving the potential prostate cancer therapy, darolutamide, the CEO of the product's originator, Orion Corp., Timo Lappalainen, has indicated the Finnish company may take a fresh look at the development priorities for its research pipeline.
Having an oncology product on the market would be a significant plus for Finland-headquartered Orion Corp, the multinational pharmaceutical company...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)